In the process of conquering difficult drug targets, we cooperate with research institutions, biotechnology companies, and pharmaceutical companies around the world at all stages of drug discovery, clinical research, and commercialization. We look for the best therapies and bring products to the global market through external licensing, product introduction, and co-development.
Commercializing drugs globally
We have entered into a global strategic collaboration agreement with AbbVie to jointly develop and commercialize SHP2 inhibitors from June 2020 to July 2023.
Click here to know more about our partnership.
On August 30, 2024, we out licensed the China rights of SHP2 inhibitor JAB-3312 and KRAS G12C inhibitor glecirasib to Allist.
Click here to know more about our partnership.
Providing new treatment options for patients
In October, 2022, we have entered into a clinical trial collaboration agreement with Merck on clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor Glecirasib (JAB-21822) and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux® (cetuximab).
Click here to know more about our partnership.
In March, 2023, we have entered into a clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combinationof Jacobio's CD73 monoclonal antibody JAB-BX102 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
Click here to know more about our partnership.
Using the latest research to bring hope to patients
Click here to know more about our partnership.
Helping with early drug discovery
Collaborations in drug R&D
Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD. Beijing ICP B 17065868-1 
京公网安备 11030102011242号